{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:25:23Z","timestamp":1789626323211,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1494,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The IV use of human immunoglobulin (hIVIG) in dogs with primary immune-mediated hemolytic anemia (IMHA) has been described previously, but herein we describe the use of high-dose IgM-enriched hIVIG (Pentaglobin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Dogs treated with high-dose Pentaglobin will experience shorter time to remission and hospital discharge and have decreased transfusion requirements compared to dogs receiving standard treatment alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fourteen client-owned dogs diagnosed with primary IMHA at specialist referral hospitals in the United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All prospectively enrolled dogs received prednisolone, dexamethasone or both along with clopidogrel. Patients were randomized to receive Pentaglobin at 1\u00a0g\/kg on up to 2 occasions, or to serve as controls. No additional immunosuppressive drugs were allowed within the first 7\u2009days of treatment. Remission was defined as stable PCV for 24\u2009hours followed by an increase in PCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten of 11 dogs from the treatment group and 2 of 3 dogs from the control group achieved remission and survived until hospital discharge. Survival and time to remission were not significantly different between groups. The volume of packed red blood cells transfused, normalized for body weight, was not significantly different between groups. Potential adverse reactions to Pentaglobin occurred in 2 dogs, but their clinical signs may have been related to the underlying disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Treatment with high-dose Pentaglobin was well tolerated by dogs with primary IMHA but no significant advantage was found in this small study. Additional studies examining larger groups and subpopulations of dogs with primary IMHA associated with a poorer prognosis are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16315","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T03:43:40Z","timestamp":1636947820000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-0565","authenticated-orcid":false,"given":"Jason P.","family":"Bestwick","sequence":"first","affiliation":[{"name":"Animal Health Trust , Suffolk,","place":["United Kingdom"]},{"name":"University of Cambridge Department of Veterinary Medicine, , Madingley Road, Cambridge, CB3 0ES,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-298X","authenticated-orcid":false,"given":"Mellora","family":"Sharman","sequence":"additional","affiliation":[{"name":"Animal Health Trust , Suffolk,","place":["United Kingdom"]},{"name":"VetCT, St John's Innovation Centre , Cowley Road, Cambridge, CB4 0WS,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat T.","family":"Whitley","sequence":"additional","affiliation":[{"name":"Davies Veterinary Specialists , Hertfordshire,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kisielewicz","sequence":"additional","affiliation":[{"name":"Pride Veterinary Centre , Derby,","place":["United Kingdom"]},{"name":"Vet Oracle Telemedicine, CVS Group , Owen Road, Diss, Norfolk, IP22 4ER,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Skelly","sequence":"additional","affiliation":[{"name":"Queen's Veterinary School , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-178X","authenticated-orcid":false,"given":"Simon","family":"Tappin","sequence":"additional","affiliation":[{"name":"Dick White Referrals, Station Farm , Cambridgeshire,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Kellett-Gregory","sequence":"additional","affiliation":[{"name":"Queen Mother Hospital for Animals, The Royal Veterinary College , Hertfordshire,","place":["United Kingdom"]},{"name":"Dick White Referrals, Station Farm , London Road, Six Mile Bottom, Cambridgeshire, CB8 0UH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Seth","sequence":"additional","affiliation":[{"name":"Animal Health Trust , Suffolk,","place":["United Kingdom"]},{"name":"Dick White Referrals, Station Farm , London Road, Six Mile Bottom, Cambridgeshire, CB8 0UH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"issue":"1","key":"2026020303510350800_jvim16315-bib-0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","article-title":"Clinical uses of intravenous immunoglobulin","volume":"142","author":"Jolles","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1476-4431.2011.00676.x","article-title":"A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin","volume":"21","author":"Spurlock","year":"2011","journal-title":"J Vet Emerg Crit Care"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0003","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0004","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database of Syst Rev"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0005","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial","volume":"20","author":"Gharebaghi","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0006","first-page":"114","article-title":"Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency","volume":"39","author":"Pourpak","year":"2006","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2230.2001.00779.x","article-title":"A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders","volume":"26","author":"Jolles","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0008","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cvsm.2020.07.015","article-title":"Use of human intravenous immunoglobulin in veterinary clinical practice","volume":"50","author":"Spurlock","year":"2020","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1024\/0036-7281.144.4.180","article-title":"Use of human intravenous immunoglobulin in dogs with primary immune mediated hemolytic anemia","volume":"144","author":"Gerber","year":"2002","journal-title":"Schweiz Arch Tierheilkd"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1939-1676.1997.tb00475.x","article-title":"Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs","volume":"11","author":"Kellerman","year":"1997","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.17236\/sat00151","article-title":"Efficacy of the combination of glucocorticoids, mycophenolate-mofetil and human immunoglobulin for the therapy of immune mediated haemolytic anaemia in dogs","volume":"160","author":"Oggier","year":"2018","journal-title":"Schweiz Arch Tierheilkd"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14405\/kjvr.2016.56.3.139","article-title":"Prognostic factors and efficacy of human intravenous immunoglobulin G in dogs with idiopathic immune-mediated hemolytic anemia: a retrospective study","volume":"56","author":"Park","year":"2016","journal-title":"Korean J Vet Res"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1476-4431.2009.00403.x","article-title":"Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia","volume":"19","author":"Whelan","year":"2009","journal-title":"J Vet Emerg Crit Care"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0014","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1939-1676.2009.0358.x","article-title":"A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs","volume":"23","author":"Bianco","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1939-1676.2007.tb03010.x","article-title":"Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs","volume":"21","author":"Bianco","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0016","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvim.12066","article-title":"A prospective randomized clinical trial of vincristine versus human intravenous immunoglobulin for acute adjunctive management of presumptive primary immune-mediated thrombocytopenia in dogs","volume":"27","author":"Balog","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0017","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5326\/0420312","article-title":"Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs","volume":"42","author":"Trotman","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5326\/JAAHA-MS-6896","article-title":"Erythema multiforme major in a dog treated with intravenous human immunoglobulin and immunosuppressive therapy","volume":"56","author":"Ramos","year":"2020","journal-title":"J Am Anim Hosp Assoc"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0019","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-4431.2009.00433.x","article-title":"Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs","volume":"19","author":"Abelson","year":"2009","journal-title":"J Vet Emerg Crit Care"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2249.2006.03098.x","article-title":"IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice","volume":"145","author":"Vassilev","year":"2006","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0021","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2567.1998.00495.x","article-title":"Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin)","volume":"94","author":"Nachbaur","year":"1998","journal-title":"Immunology"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13613-019-0501-3","article-title":"The clinical efficacy of intravenous IgM-enriched immunoglobulin (Pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis","volume":"9","author":"Cui","year":"2019","journal-title":"Ann Intensive Care"},{"key":"2026020303510350800_jvim16315-bib-0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01189","article-title":"Reversing autoimmunity combination of rituximab and intravenous immunoglobulin","volume":"9","author":"Ahmed","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0024","doi-asserted-by":"crossref","first-page":"A219","DOI":"10.1136\/archdischild-2012-302724.0762","article-title":"The use of Pentaglobulin in neonatal immune hemolytic anaemia","volume":"97","author":"Aqrabawi","year":"2012","journal-title":"Arch Dis Child"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jvim.14871","article-title":"In vitro inhibition of canine complement-mediated hemolysis","volume":"32","author":"Hernandez","year":"2017","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0026","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cvsm.2003.08.003","article-title":"Immune-mediated hemolytic anemia: understanding the nemesis","volume":"33","author":"McCullough","year":"2003","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0027","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2460\/ajvr.1998.59.12.1568","article-title":"Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes","volume":"59","author":"Reagan","year":"1998","journal-title":"Am J Vet Res"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0028","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0165-2427(97)00032-9","article-title":"Proliferative responses of peripheral blood mononuclear cells from normal dogs and dogs with autoimmune haemolytic anaemia to red blood cell antigens","volume":"59","author":"Corato","year":"1997","journal-title":"Vet Immunol Immunopathol"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvim.12028","article-title":"Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs","volume":"27","author":"Swann","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0030","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvim.15463","article-title":"ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs","volume":"33","author":"Swann","year":"2019","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0031","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2460\/javma.2001.218.543","article-title":"Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999)","volume":"218","author":"Grundy","year":"2001","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0032","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jvim.13642","article-title":"Predicting outcome in dogs with primary immune-mediated hemolytic anemia: results of a multicenter case registry","volume":"29","author":"Goggs","year":"2015","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0033","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1939-1676.2008.0060.x","article-title":"Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs","volume":"22","author":"Piek","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0034","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1476-4431.2012.00824.x","article-title":"Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia","volume":"23","author":"Kidd","year":"2013","journal-title":"J Vet Emerg Crit Care"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","article-title":"Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study","volume":"3","author":"Palabrica","year":"2013","journal-title":"Asia Pac Allergy"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0036","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1939-1676.2009.0402.x","article-title":"Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs","volume":"23","author":"Tsuchiya","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1939-1676.2010.0656.x","article-title":"A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia","volume":"25","author":"Mellett","year":"2011","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.thromres.2013.01.029","article-title":"High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition","volume":"131","author":"Bj\u00f6rkman","year":"2013","journal-title":"Thromb Res"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0039","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2460\/ajvr.71.7.822","article-title":"Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs","volume":"71","author":"Brainard","year":"2010","journal-title":"Am J Vet Res"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5326\/15473317-35-5-384","article-title":"Immune-mediated hemolytic anemia: 70 cases (1988-1996)","volume":"35","author":"Reimer","year":"1999","journal-title":"J Am Anim Hosp Assoc"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0041","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jvim.15441","article-title":"ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats","volume":"33","author":"Garden","year":"2019","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0042","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1067\/men.2003.66","article-title":"The effect of blood drawing techniques and equipment on the hemolysis of ED laboratory blood samples","volume":"29","author":"Grant","year":"2003","journal-title":"J Emerg Nurs"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0043","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/j.1365-2702.2006.02057.x","article-title":"Collecting factors related to the haemolysis of blood specimens","volume":"17","author":"Fang","year":"2008","journal-title":"J Clin Nurs"},{"issue":"1","key":"2026020303510350800_jvim16315-bib-0044","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0099-1767(96)80213-3","article-title":"A comparison of hemolysis rates using intravenous catheters versus venipuncture tubes for obtaining blood samples","volume":"22","author":"Kennedy","year":"1996","journal-title":"J Emerg Nurs"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16315","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/1\/78\/66665277\/jvim16315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/1\/78\/66665277\/jvim16315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:51:20Z","timestamp":1770108680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/36\/1\/78\/8448925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16315","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2022,1,1]]},"assertion":[{"value":"2021-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}